{"id":39489,"date":"2026-08-03T09:59:16","date_gmt":"2026-08-03T07:59:16","guid":{"rendered":"https:\/\/ggba.swiss\/pilatus-biosciences-takes-its-lausanne-born-immunotherapy-to-hong-kong\/"},"modified":"2026-08-03T10:01:49","modified_gmt":"2026-08-03T08:01:49","slug":"pilatus-biosciences-porte-a-hong-kong-une-immunotherapie-nee-a-lausanne","status":"publish","type":"post","link":"https:\/\/ggba.swiss\/fr\/pilatus-biosciences-porte-a-hong-kong-une-immunotherapie-nee-a-lausanne\/","title":{"rendered":"Pilatus Biosciences porte \u00e0 Hong Kong une immunoth\u00e9rapie n\u00e9e \u00e0 Lausanne"},"content":{"rendered":"\n

Pilatus Biosciences<\/a>, qui d\u00e9veloppe des immunoth\u00e9rapies ciblant les points de contr\u00f4le m\u00e9taboliques pour les cancers du foie et gastro-intestinaux, a re\u00e7u du D\u00e9partement de la sant\u00e9 de Hong Kong le certificat d’essai clinique pour sa th\u00e9rapie exp\u00e9rimentale principale, PLT012, chez des patients atteints de tumeurs solides avanc\u00e9es. L’entreprise a \u00e9galement cr\u00e9\u00e9 une filiale \u00e0 Hong Kong.<\/p>\n\n\n\n

Cette th\u00e9rapie trouve son origine en Suisse occidentale. Fond\u00e9e en 2022 comme spin-off de la branche lausannoise du Ludwig Institute for Cancer Research<\/a>, Pilatus d\u00e9tient une licence exclusive sur le brevet sous-jacent aupr\u00e8s de l’institut et de l’Universit\u00e9 de Lausanne<\/a>, sur la base de travaux men\u00e9s dans le laboratoire du Dr Ping-Chih Ho. L’entreprise est \u00e9tablie sur le campus des sciences de la vie Biop\u00f4le<\/a> \u00e0 Epalinges, dans le canton de Vaud, o\u00f9 elle conserve son \u00e9quipe suisse de recherche et d\u00e9veloppement.<\/p>\n\n\n\n

PLT012 est un anticorps humanis\u00e9 first-in-class ciblant CD36, un point de contr\u00f4le m\u00e9tabolique exprim\u00e9 par les lymphocytes T r\u00e9gulateurs qui contribuent \u00e0 supprimer les r\u00e9ponses immunitaires antitumorales. En bloquant l’absorption des lipides m\u00e9di\u00e9e par CD36, l’anticorps est con\u00e7u pour r\u00e9duire les populations cellulaires immunosuppressives dans le microenvironnement tumoral tout en renfor\u00e7ant l’activit\u00e9 des lymphocytes T cytotoxiques, une approche que l’entreprise a document\u00e9e dans des mod\u00e8les pr\u00e9cliniques de cancer du foie et de m\u00e9tastases h\u00e9patiques. PLT012 b\u00e9n\u00e9ficie par ailleurs du statut de m\u00e9dicament orphelin de la Food and Drug Administration am\u00e9ricaine pour le cancer du foie et des voies biliaires intrah\u00e9patiques.<\/p>\n\n\n\n

L’\u00e9tude hongkongaise sera men\u00e9e au Phase I Clinical Trial Centre, rattach\u00e9 au D\u00e9partement d’oncologie clinique de l’Universit\u00e9 chinoise de Hong Kong, avec le Dr Stephen Chan comme investigateur principal. Pilatus pr\u00e9voit de s’appuyer sur l’\u00e9cosyst\u00e8me local des sciences de la vie pour soutenir son d\u00e9veloppement clinique, ses collaborations acad\u00e9miques et strat\u00e9giques ainsi que ses \u00e9changes avec les investisseurs de la r\u00e9gion, ajoutant un troisi\u00e8me p\u00f4le \u00e0 ses implantations existantes en Suisse et \u00e0 Ta\u00efwan.<\/p>\n","protected":false},"excerpt":{"rendered":"

Pilatus Biosciences, une biotech \u00e9tablie au Biop\u00f4le dont la th\u00e9rapie principale est issue de recherches men\u00e9es \u00e0 Lausanne, a cr\u00e9\u00e9 une filiale \u00e0 Hong Kong et obtenu l’autorisation r\u00e9glementaire d’y lancer un essai clinique de PLT012 chez des patients atteints de tumeurs solides avanc\u00e9es.<\/p>\n","protected":false},"author":6,"featured_media":39486,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"mc4wp_mailchimp_campaign":[],"footnotes":""},"categories":[843],"tags":[1169,1188,1140],"class_list":["post-39489","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-sciences-de-la-vie","tag-biotech-fr-2","tag-healthcare-fr-2","tag-oncology-fr-2"],"acf":[],"yoast_head":"\nPilatus Biosciences exporte \u00e0 Hong Kong son immunoth\u00e9rapie<\/title>\n<meta name=\"description\" content=\"Pilatus Biosciences cr\u00e9e une filiale \u00e0 Hong Kong et obtient l'autorisation d'y lancer un essai clinique pour son immunoth\u00e9rapie.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ggba.swiss\/fr\/pilatus-biosciences-porte-a-hong-kong-une-immunotherapie-nee-a-lausanne\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Pilatus Biosciences exporte \u00e0 Hong Kong son immunoth\u00e9rapie\" \/>\n<meta property=\"og:description\" content=\"Pilatus Biosciences cr\u00e9e une filiale \u00e0 Hong Kong et obtient l'autorisation d'y lancer un essai clinique pour son immunoth\u00e9rapie.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ggba.swiss\/fr\/pilatus-biosciences-porte-a-hong-kong-une-immunotherapie-nee-a-lausanne\/\" \/>\n<meta property=\"og:site_name\" content=\"Greater Geneva Bern area\" \/>\n<meta property=\"article:published_time\" content=\"2026-08-03T07:59:16+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-08-03T08:01:49+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/ggba.swiss\/app\/uploads\/2026\/08\/Pilatus-Bio-Hong-Kong-1180x811-1.jpeg\" \/>\n\t<meta property=\"og:image:width\" content=\"1180\" \/>\n\t<meta property=\"og:image:height\" content=\"811\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Pierre-Yves Oehrli\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"Pierre-Yves Oehrli\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/ggba.swiss\/fr\/pilatus-biosciences-porte-a-hong-kong-une-immunotherapie-nee-a-lausanne\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/pilatus-biosciences-porte-a-hong-kong-une-immunotherapie-nee-a-lausanne\/\"},\"author\":{\"name\":\"Pierre-Yves Oehrli\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41\"},\"headline\":\"Pilatus Biosciences porte \u00e0 Hong Kong une immunoth\u00e9rapie n\u00e9e \u00e0 Lausanne\",\"datePublished\":\"2026-08-03T07:59:16+00:00\",\"dateModified\":\"2026-08-03T08:01:49+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/pilatus-biosciences-porte-a-hong-kong-une-immunotherapie-nee-a-lausanne\/\"},\"wordCount\":377,\"image\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/pilatus-biosciences-porte-a-hong-kong-une-immunotherapie-nee-a-lausanne\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2026\/08\/Pilatus-Bio-Hong-Kong-1180x811-1.jpeg\",\"keywords\":[\"Biotech\",\"Healthcare\",\"Oncology\"],\"articleSection\":[\"Sciences de la vie\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/ggba.swiss\/fr\/pilatus-biosciences-porte-a-hong-kong-une-immunotherapie-nee-a-lausanne\/\",\"url\":\"https:\/\/ggba.swiss\/fr\/pilatus-biosciences-porte-a-hong-kong-une-immunotherapie-nee-a-lausanne\/\",\"name\":\"Pilatus Biosciences exporte \u00e0 Hong Kong son immunoth\u00e9rapie\",\"isPartOf\":{\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/pilatus-biosciences-porte-a-hong-kong-une-immunotherapie-nee-a-lausanne\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/pilatus-biosciences-porte-a-hong-kong-une-immunotherapie-nee-a-lausanne\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2026\/08\/Pilatus-Bio-Hong-Kong-1180x811-1.jpeg\",\"datePublished\":\"2026-08-03T07:59:16+00:00\",\"dateModified\":\"2026-08-03T08:01:49+00:00\",\"author\":{\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41\"},\"description\":\"Pilatus Biosciences cr\u00e9e une filiale \u00e0 Hong Kong et obtient l'autorisation d'y lancer un essai clinique pour son immunoth\u00e9rapie.\",\"breadcrumb\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/pilatus-biosciences-porte-a-hong-kong-une-immunotherapie-nee-a-lausanne\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/ggba.swiss\/fr\/pilatus-biosciences-porte-a-hong-kong-une-immunotherapie-nee-a-lausanne\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/ggba.swiss\/fr\/pilatus-biosciences-porte-a-hong-kong-une-immunotherapie-nee-a-lausanne\/#primaryimage\",\"url\":\"https:\/\/ggba.swiss\/app\/uploads\/2026\/08\/Pilatus-Bio-Hong-Kong-1180x811-1.jpeg\",\"contentUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2026\/08\/Pilatus-Bio-Hong-Kong-1180x811-1.jpeg\",\"width\":1180,\"height\":811,\"caption\":\"Pilatus Biosciences d\u00e9veloppe des immunoth\u00e9rapies ciblant les points de contr\u00f4le m\u00e9taboliques, \u00e0 partir de recherches men\u00e9es au Ludwig Institute for Cancer Research \u00e0 Lausanne. | \u00a9 Pilatus Biosciences\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/ggba.swiss\/fr\/pilatus-biosciences-porte-a-hong-kong-une-immunotherapie-nee-a-lausanne\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/ggba.swiss\/fr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Pilatus Biosciences porte \u00e0 Hong Kong une immunoth\u00e9rapie n\u00e9e \u00e0 Lausanne\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#website\",\"url\":\"https:\/\/staging.ggba.swiss\/en\/\",\"name\":\"Greater Geneva Bern area\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/staging.ggba.swiss\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41\",\"name\":\"Pierre-Yves Oehrli\",\"url\":\"https:\/\/ggba.swiss\/fr\/author\/pierre-yves-oehrli\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Pilatus Biosciences exporte \u00e0 Hong Kong son immunoth\u00e9rapie","description":"Pilatus Biosciences cr\u00e9e une filiale \u00e0 Hong Kong et obtient l'autorisation d'y lancer un essai clinique pour son immunoth\u00e9rapie.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ggba.swiss\/fr\/pilatus-biosciences-porte-a-hong-kong-une-immunotherapie-nee-a-lausanne\/","og_locale":"fr_FR","og_type":"article","og_title":"Pilatus Biosciences exporte \u00e0 Hong Kong son immunoth\u00e9rapie","og_description":"Pilatus Biosciences cr\u00e9e une filiale \u00e0 Hong Kong et obtient l'autorisation d'y lancer un essai clinique pour son immunoth\u00e9rapie.","og_url":"https:\/\/ggba.swiss\/fr\/pilatus-biosciences-porte-a-hong-kong-une-immunotherapie-nee-a-lausanne\/","og_site_name":"Greater Geneva Bern area","article_published_time":"2026-08-03T07:59:16+00:00","article_modified_time":"2026-08-03T08:01:49+00:00","og_image":[{"width":1180,"height":811,"url":"https:\/\/ggba.swiss\/app\/uploads\/2026\/08\/Pilatus-Bio-Hong-Kong-1180x811-1.jpeg","type":"image\/jpeg"}],"author":"Pierre-Yves Oehrli","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"Pierre-Yves Oehrli","Dur\u00e9e de lecture estim\u00e9e":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/ggba.swiss\/fr\/pilatus-biosciences-porte-a-hong-kong-une-immunotherapie-nee-a-lausanne\/#article","isPartOf":{"@id":"https:\/\/ggba.swiss\/fr\/pilatus-biosciences-porte-a-hong-kong-une-immunotherapie-nee-a-lausanne\/"},"author":{"name":"Pierre-Yves Oehrli","@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41"},"headline":"Pilatus Biosciences porte \u00e0 Hong Kong une immunoth\u00e9rapie n\u00e9e \u00e0 Lausanne","datePublished":"2026-08-03T07:59:16+00:00","dateModified":"2026-08-03T08:01:49+00:00","mainEntityOfPage":{"@id":"https:\/\/ggba.swiss\/fr\/pilatus-biosciences-porte-a-hong-kong-une-immunotherapie-nee-a-lausanne\/"},"wordCount":377,"image":{"@id":"https:\/\/ggba.swiss\/fr\/pilatus-biosciences-porte-a-hong-kong-une-immunotherapie-nee-a-lausanne\/#primaryimage"},"thumbnailUrl":"https:\/\/ggba.swiss\/app\/uploads\/2026\/08\/Pilatus-Bio-Hong-Kong-1180x811-1.jpeg","keywords":["Biotech","Healthcare","Oncology"],"articleSection":["Sciences de la vie"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/ggba.swiss\/fr\/pilatus-biosciences-porte-a-hong-kong-une-immunotherapie-nee-a-lausanne\/","url":"https:\/\/ggba.swiss\/fr\/pilatus-biosciences-porte-a-hong-kong-une-immunotherapie-nee-a-lausanne\/","name":"Pilatus Biosciences exporte \u00e0 Hong Kong son immunoth\u00e9rapie","isPartOf":{"@id":"https:\/\/staging.ggba.swiss\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/ggba.swiss\/fr\/pilatus-biosciences-porte-a-hong-kong-une-immunotherapie-nee-a-lausanne\/#primaryimage"},"image":{"@id":"https:\/\/ggba.swiss\/fr\/pilatus-biosciences-porte-a-hong-kong-une-immunotherapie-nee-a-lausanne\/#primaryimage"},"thumbnailUrl":"https:\/\/ggba.swiss\/app\/uploads\/2026\/08\/Pilatus-Bio-Hong-Kong-1180x811-1.jpeg","datePublished":"2026-08-03T07:59:16+00:00","dateModified":"2026-08-03T08:01:49+00:00","author":{"@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41"},"description":"Pilatus Biosciences cr\u00e9e une filiale \u00e0 Hong Kong et obtient l'autorisation d'y lancer un essai clinique pour son immunoth\u00e9rapie.","breadcrumb":{"@id":"https:\/\/ggba.swiss\/fr\/pilatus-biosciences-porte-a-hong-kong-une-immunotherapie-nee-a-lausanne\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ggba.swiss\/fr\/pilatus-biosciences-porte-a-hong-kong-une-immunotherapie-nee-a-lausanne\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/ggba.swiss\/fr\/pilatus-biosciences-porte-a-hong-kong-une-immunotherapie-nee-a-lausanne\/#primaryimage","url":"https:\/\/ggba.swiss\/app\/uploads\/2026\/08\/Pilatus-Bio-Hong-Kong-1180x811-1.jpeg","contentUrl":"https:\/\/ggba.swiss\/app\/uploads\/2026\/08\/Pilatus-Bio-Hong-Kong-1180x811-1.jpeg","width":1180,"height":811,"caption":"Pilatus Biosciences d\u00e9veloppe des immunoth\u00e9rapies ciblant les points de contr\u00f4le m\u00e9taboliques, \u00e0 partir de recherches men\u00e9es au Ludwig Institute for Cancer Research \u00e0 Lausanne. | \u00a9 Pilatus Biosciences"},{"@type":"BreadcrumbList","@id":"https:\/\/ggba.swiss\/fr\/pilatus-biosciences-porte-a-hong-kong-une-immunotherapie-nee-a-lausanne\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/ggba.swiss\/fr\/"},{"@type":"ListItem","position":2,"name":"Pilatus Biosciences porte \u00e0 Hong Kong une immunoth\u00e9rapie n\u00e9e \u00e0 Lausanne"}]},{"@type":"WebSite","@id":"https:\/\/staging.ggba.swiss\/en\/#website","url":"https:\/\/staging.ggba.swiss\/en\/","name":"Greater Geneva Bern area","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/staging.ggba.swiss\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Person","@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41","name":"Pierre-Yves Oehrli","url":"https:\/\/ggba.swiss\/fr\/author\/pierre-yves-oehrli\/"}]}},"_links":{"self":[{"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/posts\/39489","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/comments?post=39489"}],"version-history":[{"count":1,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/posts\/39489\/revisions"}],"predecessor-version":[{"id":39491,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/posts\/39489\/revisions\/39491"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/media\/39486"}],"wp:attachment":[{"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/media?parent=39489"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/categories?post=39489"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/tags?post=39489"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}